2.1
Targeted-release budesonide (Kinpeygo, Britannia) is indicated for 'the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram'.
2 Information about targeted-release budesonide
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for targeted-release budesonide.
Price
2.3
The list price of targeted-release budesonide is £6,528.54 for a 120‑pack of 4‑mg modified-release hard capsules.
2.4
The company has a commercial arrangement. This makes targeted-release budesonide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.